Archives: Commentaries

PHI recently joined forces with the Huntsman Cancer Institute in the battle against cancer. Using PHI’s HoloMonitor technology, the researchers at Huntsman aim to develop methods quantifying the phenomena known as epithelial–mesenchymal transition (EMT).

Single-cell analysis aided by supercomputing and artificial intelligence is set to revolutionize biomedical research over the next decade.

Using HoloMonitor’s unique capability to non-invasively image and quantify cellular behavior over long time periods, scientists at the National Institute of Aging aim to understand how the heart’s “brain cells” contribute to aging.

Using HoloMonitor and the latest gene editing techniques, scientists at University of California, San Francisco have uncovered the mechanisms leading to invasive melanoma.

By studying a primitive form of bacteria researchers at Queensland University of Technology in Australia have developed a new drug that has the potential to dramatically slow the aging process. Using HoloMonitor the researchers could see how old and damaged cells became young again. The promising results were recently reported by Australian television.

To transform an invention to a product that can be purchased by any scientist is the often unappreciated but crucial role of commercializing enterprises. This was the underlying theme of my presentation at SPIE 2018, “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”.

The special issue and the increasing number of scientific publications by HoloMonitor customers, and others, leave no room for doubt. Label-free time-lapse cytometry has begun to fulfill its promise to medical science — a leap of understanding.